Emerging technologies focused on
Improving Patient Outcomes
for cost effective healthcare

 

Our Mission

Although there has been great advances in the understanding and treatment of cancer, this disease today is largely detected and diagnosed with the same procedures and technology that has been used for generations. The same is true for measuring an individual’s response to therapy. These methods are inefficient, painful and expensive. NuView wants to change this. We are developing a compelling and innovative way to detect, diagnose and personalize the treatment of cancer.

Strong IP Pipeline

  • Urine screen to detect prostate and bladder cancer
  • Imaging agent to diagnose prostate and breast cancer
  • Imaging agent to assess tumor response to therapy

DEVELOPING BREAKTHROUGH TECHNOLOGIES

  • Replace PSA testing with accurate and early detection
  • Eliminate invasive diagnostic procedures by visualizing disease
  • Personalize therapies with rapid assessment of tumor response

video-play

What is PET Imaging?

Images produced from new medical technologies that incorporate PET (positron emission tomography) are similar to a weather map you see on your local news.

Play Video

Read More

img-portfolio

Our NLS-VPAC1 Technology Platform

Our patented imaging agent binds to a receptor (called VPAC1) on the surface of many cancer cells.   We are utilizing this technology to create a urine screen to detect prostate/bladder cancer and an imaging agent to transform the diagnosis of breast and prostate cancer.

Learn more

img-shopping

Our NLS-FMAU Imaging Agent

Our patented imaging agent directly visualizes the cellular proliferation of a tumor.  We are developing this product to rapidly assess an individual’s response to cancer therapy.

Learn more

Market Readiness Progress (at 100%)

NLS-VPAC1 - Prostate / Bladder Cancer Urine Screen @ Analytical Validation

NLS-VPAC1 - Breast Cancer Imaging @ Phase 1

NLS-VPAC1 - Prostate Cancer Imaging @ Phase 1 Ongoing

NLS-FMAU - Cancer Tumor Treatment Planning and Therapy Response @ Phase 1 Ongoing

Management Team

  • Paul Crowe

    Chairman & CEO

    About Paul Crowe

    Mr. Crowe is the founder of NuView Life Sciences and has served as Chairman and Chief Executive Officer since 2005. Mr. Crowe’s experience includes early-stage company development, strategic planning, capital formation, M&A, and public offerings. Over the past 40 years, Mr. Crowe has commercialized novel medical imaging technologies, such as diagnostic ultrasound with Philips Medical Systems, magnetic resonance imaging (MRI) with Diasonics NMR and positron emission tomography (PET) with Mobile PET Systems. Mr. Crowe developed several medical service provider businesses utilizing the technologies described above building high-performance management, sales and operations teams to drive technology adoption and revenue growth.

  • Thomas Brown

    Vice President Finance

    About Thomas Brown

    Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets, as well as, businesses. Mr. Brown is the founding partner of three investment-banking firms, a private equity firm, and two investment management firms. Mr. Brown has served as the CFO of several public and private companies, as well as, non-profit organization and focused on coordinating the reporting and management of the financial infrastructure for emerging growth businesses and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies.   Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.  Mr. Brown is an Adjunct Professor in the Argyros School of Business & Finance at Chapman University where he teaches Entrepreneurial Finance.

  • Steven J. Davis

    Legal Counsel

    About Steven J. Davis

    Mr. Davis has over twenty years’ experience in corporate, securities, and business law, with extensive experience in emerging growth companies.  Mr. Davis is also a founding partner of Rancho Santa Fe Partners, a strategic advisory firm that supports emerging growth companies.  Mr. Davis has served as General Counsel and an executive officer for several public and privately held companies, and has clients which include International Stem Cell (ISCO), Amylin Pharmaceuticals (AMLN), Leap Wireless (LEAP), BillMyParents (BMPI), Mitek (MITK), and SugarMade (SGMD).  Mr. Davis is on the Board of Directors and Audit, Compensation and Nominating Committees (Chairman) of Telanetix (TNIX), a publicly traded telecommunications company, and on the Board of Directors of Theragene, a privately held life sciences company.  Mr. Davis practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP, where he advised both private and public clients in a variety of transactions.  Mr. Davis received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law. He received his B.A. in Political Science, Cum Laude, from Arizona State University.

  • Peter S. Conti, MD

    Medical Director

    About Peter S. Conti, MD

    Dr. Conti has served as the Company’s Medical Director and Director of the Company since October 2004.  Dr. Conti is a Professor of Radiology, Pharmacy, and Biomedical Engineering at the University of Southern California, as well as Director of its Positron Imaging Science Center and Clinic. Dr. Conti received his medical degree from Cornell University and completed his residency in Diagnostic Radiology and fellowship in Nuclear Medicine at The Johns Hopkins Medical Institution. He is board-certified in both Diagnostic Radiology and Nuclear Medicine. Dr. Conti currently serves on the Board of Directors and is a past-president of the Society of Nuclear Medicine (SNM). Dr Conti also serves on a number of committees for the SNM that is focused on the development of the PET technology and its applications in medicine, including those involving government and regulatory affairs.

  • Stuart Foster

    Director

    About Stuart Foster

    Mr. Foster brings to the Company’s board a strong management background in various aspects of the healthcare industry. From 2000-2008, Mr. Foster served as Corporate Vice President of Edwards Life Sciences and coordinated the spin-off of Edwards from Baxter International into a NYSE listed company in April 2001. Mr. Foster was president Global Operations for Baxter International from 1994 to 2000, where he managed the vascular and critical care business. From 1990 to 1994, Mr. Foster was president of Intramed Laboratories, a venture funded development Stage Company, which was focused on developing the technology for disposable endoscopy products that subsequently went public and was sold to Baxter International. In 1983 to 1989, he was vice president and general manager of Sensor medics, the advanced technology operations group of Beckman Instruments, where he coordinated a leverage buyout of the business that became the leader in anesthesia monitoring and exercise physiology equipment and was subsequently sold to Thermo-Electron.

  • Thomas McCausland

    Director

    About Thomas McCausland

    Mr. McCausland joined the Company as a Director in October 2007. Over Mr. McCausland’s 40-year business career, he has served in senior executive positions with Westinghouse Electric Corporation and Siemens. From 1997 through 2006, he served as President of the Siemens Medical Customer Solutions Group and grew revenues from $1 billion to over $4 billion during his tenure. In addition to serving as an advisor to the Radiological Society of North America and several other healthcare companies, Mr. McCausland also served as chairman of the Siemens Foundation dedicated to improving math and science education in high schools.

  • Michael Nobel PH.D.

    Director

    About Michael Nobel PH.D.

    Michael Nobel participated in the introduction of magnetic resonance imaging in 1980 and remained in that field for 26 years. Today he is chairman or board member of seven international companies in diagnostics, treatment and information systems in the field of medicine.

    For 15 years Michael Nobel represented the Nobel family as vice chairman and chairman of its board of directors. He is founder and chairman of the Nobel Sustainable Trust.  He is chairman or board member of eight non-for-profit organizations in the field of youth education and development and peace and conflict resolution.

    Michael Nobel was visiting professor at the Frontier Research Institute at the Tokyo Institute of Technology between 2007 and 2012. He is currently a senior fellow at the Centre for the Study of World Civilizations at Tokyo Tech and a guest professor at Seisa University.

    In 2005 in Jerusalem he received the Albert Einstein Medal for Outstanding Achievements in Life Sciences and Technology and in 2006 the International Order of Perfection in Moscow. In 2013 he received the Order of Duty and Honor from the United Nations Council for Public Awards and the Gold Medal from the IINC in Tambov, Russia. The World Federation of Consuls presented him its Order of Merit in 2014.

    Michael Nobel obtained a doctorate at the University of Lausanne in psycho-pedagogy.

  • William G. Bradley, Jr. MD

    Advisor

    About William G. Bradley, Jr. MD

    Dr. Bradley serves as a consultant facilitating the needs for the new MRI/PET integrated imaging systems now beginning to be shipped from the major medical device manufactures. Dr. Bradley is Chairman of the Department of Radiology at the University of California, San Diego since 2002. Dr. Bradley received his B.S. at the California Institute of Technology and his Ph.D. at Princeton University, both in Chemical Engineering. Dr. Bradley completed all of his medical training at the University of California, San Francisco. Dr. Bradley was the Director of MRI at both the Huntington Medical Research Institute from 1982 to 1989 and Long Beach Memorial Medical Center from 1990 to 2002. Dr. Bradley was also Professor of Radiology at UC Irvine from 1994 to 2002. He is past-president of the International Society of Magnetic Resonance in Medicine and has won its two highest honors for his research, the Gold Medal and Honorary Member.

  • Brian Dowd, Ph.D.

    Vice President of Clinical and Scientific Affairs

    About Brian Dowd, Ph.D.

    Dr. Dowd brings to the Company over 11 years of drug development experience in the Pharmaceutical industry.  Dr. Dowd has served in a variety of roles during his career, including preclinical research in Oncology and Alzheimer’s Disease, strategic planning, clinical development, medical affairs, and in-licensing.  Prior to joining NuView Life Sciences, Dr. Dowd served as Associate Director of Clinical and Scientific Affairs at Myrexis, Inc. (previously Myriad Pharmaceuticals Inc.) and preclinical drug development positions at Sugen, Inc.  He graduated from the University of Michigan, Ann Arbor with a B.S. in Biology and earned his Ph.D. at the Yale University School of Medicine in the Department of Cellular and Molecular Physiology.

The NLS-VPAC1 is a powerful tool to detect and visualize a variety of cancers at the earliest stage of disease.

 

 

Want to Learn More About NuView?

We welcome inquiries with interested individuals, media and potential investors. Please drop us a note in the contact form or call us directly.

Contact Address

NuView Life Sciences, Inc
1107 Snowberry St
Park City, UT 84098

Contact Details

TEL 888.902.7779
FAX 435.647.5602

Office Hours

9am to 5pm MST
Monday to Friday